Overview

• The deals cover Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceuticals, concluding AbbVie’s 2023 patent lawsuit.
• AbbVie says, assuming pediatric exclusivity and absent acceleration triggers, no U.S. upadacitinib tablet generics are expected before April 2037.
• Analysts called the extension a clear positive, citing added runway for Rinvoq and raising peak-sales scenarios, with William Blair modeling up to $19 billion in global peak revenue.
• Rinvoq generated $5.97 billion in 2024 and $3.75 billion in the first half of 2025, with second-quarter sales up about 42% year over year.
• AbbVie is advancing Rinvoq in alopecia areata, vitiligo, hidradenitis suppurativa and lupus, reporting positive Phase 3 alopecia results and estimating roughly $2 billion in added peak sales from the next wave of approvals.